James Edeerfield Management... Net Worth

The estimated Net Worth of James Edeerfield Management... is at least 8.85 百万$ dollars as of 15 July 2024. James Management owns over 11,766,000 units of BiomX Inc stock worth over 8,848,669$ and over the last few years James sold PHGE stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

James Management PHGE stock SEC Form 4 insiders trading

James has made over 1 trades of the BiomX Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently James exercised 11,766,000 units of PHGE stock worth 11,648,340$ on 15 July 2024.

The largest trade James's ever made was exercising 11,766,000 units of BiomX Inc stock on 15 July 2024 worth over 11,648,340$. On average, James trades about 3,922,000 units every 0 days since 2024. As of 15 July 2024 James still owns at least 8,938,049 units of BiomX Inc stock.

You can see the complete history of James Management stock trades at the bottom of the page.

Insiders trading at BiomX Inc

Over the last 5 years, insiders at BiomX Inc have traded over 332,366$ worth of BiomX Inc stock and bought 1,036,414 units worth 787,614$ . The most active insiders traders include James Edeerfield Management...、Chidozie Ugwumba、Erez Chimovits. On average, BiomX Inc executives and independent directors trade stock every 68 days with the average trade being worth of 533,749$. The most recent stock trade was executed by James Edeerfield Management... on 15 July 2024, trading 11,766,000 units of PHGE stock currently worth 11,648,340$.

What does BiomX Inc do?

biomx is a microbiome drug discovery company developing customized phage therapies that target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (ibd) and cancer. we discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets. the company’s platforms use computational and synthetic biology and cutting-edge research from profs. rotem sorek, ph.d., eran elinav, m.d., ph.d., and eran segal, ph.d., of the weizmann institute of science; and professor timothy k. lu, m.d., ph.d., of the massachusetts institute of technology. investors in the company include orbimed israel incubator lp, johnson & johnson development corporation inc., takeda ventures, inc., seventure partners, mirae asset global investments, and sbi.

Complete history of James Management stock trades at BiomX Inc

BiomX Inc executives and stock owners

BiomX Inc executives and other stock owners filed with the SEC include:

• Jonathan Solomon,
  Chief Executive Officer, Director
• Sailaja Puttagunta,
  Chief Medical Officer
• Assaf Oron,
  Chief Business Officer
• Dr. Merav Bassan Ph.D.,
  Chief Devel. Officer
• Russell Greig,
  Independent Chairman of the Board
• Lynne Sullivan,
  Independent Director
• Paul Sekhri,
  Independent Director
• Alan Moses,
  Independent Director
• Jonas Grossman,
  Independent Director
• Gbola Amusa,
  Independent Director
• Merav Bassan,
  Chief Development Officer
• Marina Wolfson,
  Principal Financial Officer, Vice President - Finance and Operations
• Dr. Regis A. Vilchez M.D., Ph.D.,
  Sr. VP & Head of Clinical Devel.
• Dr. Inbar Gahali-Sass,
  VP of Platform R&D
• Dr. Timothy K. Lu M.D., Ph.D.,
  Scientific Founder
• Dr. Eran Elinav M.D., Ph.D.,
  Scientific Founder
• Inbal Benjamini-Elran,
  VP of HR
• Noel Kurdi,
  VP of Investor Relations & Strategy
• Prof. Timothy K. Lu,
  Scientific Founder
• Dr. Eran Elinav,
  Scientific Founder
• Prof. Rotem Sorek Ph.D.,
  Scientific Founder
• Assaf Oron,
  Chief Bus. Officer
• Yaron Breski,
  Director
• Erez Chimovits,
  Director
• Thomas Layton Walton,
  10% owner
• Eddie Williams,
  Director
• Kerry Mountain Wood Llc Pro...,
  
• Israel Bio Fund Gp Limited ...,
  
• Chidozie Ugwumba,
  
• Susan Blum,
  Director
• Gregory Louis Merril,
  Director
• Jonathan S Leff,
  Director
• Jesse Goodman,
  Director
• James Edeerfield Management...,
  
• Israel Bio Fund Gp Limited ...,
  
• James Edeerfield Management...,
  
• Jason M. Marks,
  Director
• Michael E. Dambach,
  Director
• Fibrosis Foundation Cystic,